Why the study?
Does pretreatment with magnolol or honokiol reduce ventricular arrhythmia during acute coronary occlusion in rats?
Does pretreatment with magnolol or honokiol reduce ventricular arrhythmia during acute coronary occlusion in rats?
Magnolol and honokiol protect against ischemia-induced ventricular arrhythmias in rats, an effect likely mediated by increased nitric oxide synthesis.
May support NO-mediated antiarrhythmic effects in rat ischemia; hypothesis-generating and should not yet change practice.
This study was designed to evaluate the in vivo effect of magnolol and honokiol on the acute phase of coronary ligation in the presence of nitric oxide inhibitor (L-NAME) or cyclooxygenase inhibitor (aspirin). After Sprague-Dawley rats were anesthetized with urethane, the changes of ventricular arrhythmia induced by coronary ligation for 30 min were determined with or without pretreatment with study medications. The incidence and duration of ventricular arrhythmia were significantly reduced after intravenous pretreatment (15 min before coronary ligation) with 10(-7) g/kg magnolol or 10(-7) g/kg honokiol. However, the antiarrhythmic effect of magnolol or honokiol could be abolished with the pretreatment of 1 mg/kg L-NAME, but not with pretreatment of 100 mg/kg aspirin. The abolishment of the myocardial beneficial effect of magnolol and honokiol by L-NAME, instead of aspirin, suggests an involvement of an increased nitric oxide synthesis in the protection offered by magnolol and honokiol against arrhythmia during myocardial ischemia.
No takes yet. Share an insight, caveat, or question.
Tsai et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: